You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Colorectal cancer

Capecitabine and oxaliplatin in the adjuvant treatment of stage 3 (Dukes' C) colon cancer

  • Technology appraisal guidance
  • Reference number: TA100
  • Published:  26 April 2006
  • Guidance
  • Tools and resources
  • Information for the public
  • History
Download guidance (PDF)
  • Overview
  • 1 Recommendations
  • 2 Clinical need and practice
  • 3 The technologies
  • 4 Evidence and interpretation
  • 5 Recommendations for further research
  • 6 Implementation and audit
  • 7 Appraisal committee members and NICE project team
  • 8 Sources of evidence considered by the committee
  • Appendix A Detail on criteria for audit of the use of capecitabine and oxaliplatin in the adjuvant treatment of stage 3 (Dukes' C) colon cancer
  • Update information

Update information

Minor changes since publication

March 2014: Implementation section updated to clarify that capecitabine and oxaliplatin are recommended as options for treating stageĀ 3 (Dukes' C) colon cancer. Additional minor maintenance update also carried out.

ISBN: 978-1-4731-5671-5


Previous page Appendix A Detail on criteria for audit of the use of capecitabine and oxaliplatin in the adjuvant treatment of stage 3 (Dukes' C) colon cancer
Back to top